|
OSI Pharmaceuticals Initiates Clinical Development Program For Anti-Diabetes Candidate, PSN821 (Medical News Today)
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced that it has initiated a first-in-human clinical study for its G-protein coupled receptor GPR119 agonist, PSN821, which the Company is developing for the treatment of type 2 diabetes.
us.rd.yahoo.com
Rhode Island Hospital study finds link between obesity, type 2 diabetes and neurodegeneration (EurekAlert!)
( Lifespan ) New research from Rhode Island Hospital found that obesity and type 2 diabetes mellitus can contribute to mild neurodegeneration with features common with Alzheimer's disease -- the first study to show that obesity can cause neurodegeneration.
us.rd.yahoo.com
New diabetes cell therapy is suggested (UPI)
TEL AVIV, Israel, Sept. 3 (UPI) -- Israeli scientists say they have developed a method of replicating insulin-producing beta cells, suggesting a new treatment for type 1 diabetes.
us.rd.yahoo.com
Study to Explore the Link Between Periodontal Treatment and Medical Costs for People With Diabetes (PR Newswire via Yahoo! Finance)
Researchers from the Delta Dental Research and Data Institute and the University of Michigan School of Dentistry are studying the impact that periodontal treatment may have on the medical costs of people with diabetes.
us.rd.yahoo.com
New diabetes cell therapy is suggested (Moldova.org)
Israeli scientists say they have developed a method of replicating insulin-producing beta cells, suggesting a new treatment for type 1 diabetes.Researchers led by Tel Aviv University Professor Shimon Efrat have developed a way to cultivate, in the laboratory, insulin-producing beta cells derived from human tissue. If such new healthy cells can be implanted into type 1 diabetes patients, the ...
us.rd.yahoo.com
OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Diabetes Candidate, PSN821 (Centre Daily Times)
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has initiated a first-in-human clinical study for its G-protein coupled receptor GPR119 agonist, PSN821, which the Company is developing for the treatment of type 2 diabetes. Discovered by OSI's diabetes and obesity research team, PSN821 demonstrated both effective glucose lowering and substantial reductions of body weight in ...
us.rd.yahoo.com
Novel Short-Term Weight-Loss Approach Works Long-Term for Type 2 Diabetes (Newswise)
A study by researchers from the Joslin Diabetes Center has shown for the first time that more than half of patients with type 2 diabetes who enrolled in a novel short-term weight management program were able to maintain the weight loss they achieved during the program on their own long-term.
us.rd.yahoo.com
Physicians Eager To Increase Their First- And Second-Line Prescriptions For Januvia Over The Next Two Years For The ... (Medical News Today)
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Merck's Januvia is currently prescribed most often as a third- or later-line of therapy for the treatment of type 2 diabetes.
us.rd.yahoo.com
OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Diabetes Candidate, PSN821 (Business Wire via Yahoo! Finance)
MELVILLE, N.Y.----OSI Pharmaceuticals, Inc. announced today that it has initiated a first-in-human clinical study for its G-protein coupled receptor GPR119 agonist, PSN821, which the Company is developing for the treatment of type 2 diabetes.
us.rd.yahoo.com
Diabetics Missing Out on Life Saving Medication (PR Newswire via Yahoo! Finance)
One in four patients with diabetes are not receiving the appropriate cardiovascular medications, research launched at the British Pharmaceutical Conference in Manchester has shown.
us.rd.yahoo.com
|
